Article info

Protocol
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma

Authors

  • Jonas S Heitmann Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, GermanyCluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Juliane S Walz Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, GermanyCluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Martin Pflügler Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, GermanyInstitute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Joseph Kauer Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Richard F Schlenk National Center of Tumor Diseases-Trial Center, National Center of Tumor Diseases, German Cancer Research Center, Heidelberg, GermanyDepartment of Internal Medicine VI, Heidelberg University Hospital, Heidelberg, GermanyDepartment of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Gundram Jung Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Helmut R Salih Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, GermanyCluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Helmut R Salih; helmut.salih{at}med.uni-tuebingen.de
View Full Text

Citation

Heitmann JS, Walz JS, Pflügler M, et al
Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma

Publication history

  • Received April 21, 2020
  • Revised August 20, 2020
  • Accepted August 24, 2020
  • First published October 16, 2020.
Online issue publication 
October 16, 2020
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.